Saccomano Nicholas A sold OKUR

August 7, 2026 · Form 4 insider transaction

Saccomano Nicholas A sold 2,359 shares of OnKure Therapeutics, Inc., a transaction worth N/A. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 4 days after the transaction.

Direction
Disposed (sell-side)
Shares
2,359
Price
N/A
Total value
N/A
RoleOfficer, Director
SecurityEmployee Stock Option (right to buy)
Transaction codeD: Disposition to the issuer
Transaction dateAugust 7, 2026
Filing dateAugust 11, 2026
Shares owned after0
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.; Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.; All of the shares subject to this option are fully vested and exercisable as of the date hereof.

View the original Form 4 on SEC EDGAR